Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 5, Pages 1594
Publisher
MDPI AG
Online
2020-05-25
DOI
10.3390/jcm9051594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
- (2020) Nizar M. Tannir et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro
- (2020) Markus Krebs et al. Journal of Clinical Medicine
- Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression.
- (2020) Antonio G. Solimando et al. HAEMATOLOGICA
- MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
- (2020) Vanessa Desantis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?
- (2020) Alessia Mennitto et al. Journal of Clinical Medicine
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
- (2019) Nieves Martínez Chanzá et al. LANCET ONCOLOGY
- Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors
- (2019) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma
- (2019) Jessica Carlsson et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes
- (2019) Eleonora A. Braga et al. Frontiers in Genetics
- PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN
- (2019) Abdallah Flaifel et al. CLINICAL CANCER RESEARCH
- The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
- (2019) W. Marston Linehan et al. Nature Reviews Urology
- High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
- (2019) Antonio Giovanni Solimando et al. Journal of Clinical Medicine
- Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
- (2019) Antonella Argentiero et al. Cancers
- Targeting the Tumor Microenvironment in Renal Cell Cancer Biology and Therapy
- (2019) Isabel Heidegger et al. Frontiers in Oncology
- Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment
- (2019) Tianyi Liu et al. Frontiers in Cell and Developmental Biology
- Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
- (2019) Daniel J. George et al. ONCOLOGIST
- Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
- (2019) Lynda Vuong et al. Cancer Discovery
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- (2019) David A. Braun et al. JAMA Oncology
- LBA57Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)
- (2019) M-O Grimm et al. ANNALS OF ONCOLOGY
- Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
- (2019) Bernard Escudier et al. EUROPEAN UROLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
- (2019) Longo et al. Medicina-Lithuania
- Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
- (2019) Oronzo Brunetti et al. Medicina-Lithuania
- Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs
- (2019) Patrizia Leone et al. Journal of Clinical Medicine
- The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
- (2019) Nicole Brighi et al. Cancers
- Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
- (2019) Lucía Carril-Ajuria et al. Cancers
- Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer
- (2019) Carmine D'Aniello et al. Frontiers in Oncology
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
- (2018) Annelies Verbiest et al. Clinical Genitourinary Cancer
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy
- (2018) Annelies Verbiest et al. EUROPEAN UROLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms
- (2018) Rossana Berardi et al. PLoS One
- Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis
- (2018) Elvira Schmidt et al. Targeted Oncology
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis
- (2018) Chris P. Miller et al. NEOPLASIA
- MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma
- (2018) Fajun Qu et al. JOURNAL OF DRUG TARGETING
- Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors
- (2018) Matthew D. Young et al. SCIENCE
- Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol
- (2018) Andrea Casadei Gardini et al. TUMORI
- Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes
- (2018) Maria Antonia Frassanito et al. JOURNAL OF PATHOLOGY
- Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
- (2018) Martin H Voss et al. LANCET ONCOLOGY
- Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma
- (2018) Walter Henriques da Costa et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients
- (2018) Patrizia Leone et al. OncoImmunology
- Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
- (2017) J. Connor Wells et al. EUROPEAN UROLOGY
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- MicroRNAs Associated with Von Hippel–Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review
- (2017) Lisa-Maria Schanza et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
- (2017) Qingshui Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape
- (2017) Stefan B. Eichmüller et al. JNCI-Journal of the National Cancer Institute
- The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein
- (2017) Imen Jridi et al. TOXICON
- Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients
- (2017) Lei Liu et al. BioScience Trends
- Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review
- (2017) Bum Jun Kim et al. Oncotarget
- Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
- (2017) Martina Rudelius et al. HAEMATOLOGICA
- Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape
- (2017) Stefan B. Eichmüller et al. JNCI-Journal of the National Cancer Institute
- Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).
- (2017) Y. Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of CXCR4 expression to predict the efficacy of sorafenib treatment in patients with metastatic renal cell carcinoma.
- (2017) J. Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways
- (2016) Pengcheng Sun et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma
- (2016) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Targeting renal cell carcinoma with a HIF-2 antagonist
- (2016) Wenfang Chen et al. NATURE
- Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
- (2016) Xiaoyan Liu et al. Oncotarget
- Microenvironment drug resistance in multiple myeloma: emerging new players
- (2016) Lucia Di Marzo et al. Oncotarget
- Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma
- (2016) Simon Jasinski-Bergner et al. Oncotarget
- Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
- (2016) Fengju Chen et al. Cell Reports
- Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
- (2015) Matteo Santoni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies
- (2015) Brian Rini et al. LANCET ONCOLOGY
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
- (2015) Jenny J Ko et al. LANCET ONCOLOGY
- miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma
- (2015) Heba W Z Khella et al. MOLECULAR THERAPY
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma
- (2015) Yu-Zheng Ge et al. Scientific Reports
- Specific Genomic Aberrations Predict Survival, But Low Mutation Rate in Cancer Hot Spots, in Clear Cell Renal Cell Carcinoma
- (2015) Linda Köhn et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma
- (2014) Robert J. Motzer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
- (2014) Sakshi Gulati et al. EUROPEAN UROLOGY
- The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters
- (2013) Brett Delahunt et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis
- (2013) G S Wong et al. BRITISH JOURNAL OF CANCER
- Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
- (2013) Nils Kroeger et al. CANCER
- Modification of the Tumor Microenvironment as a Novel Target of Renal Cell Carcinoma Therapeutics
- (2013) James H. Finke et al. CANCER JOURNAL
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
- (2013) Payal Kapur et al. LANCET ONCOLOGY
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
- (2013) Daniel YC Heng et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- MiR-221 and miR-130a Regulate Lung Airway and Vascular Development
- (2013) Sana Mujahid et al. PLoS One
- Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey
- (2013) Daniele Santini et al. PLoS One
- Renal Cell Carcinoma Associated With Transcription Factor E3 Expression and Xp11.2 Translocation
- (2012) Tobias Klatte et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The experimental renal cell carcinoma model in the chick embryo
- (2012) Patricia Fergelot et al. ANGIOGENESIS
- High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
- (2012) C. D'Alterio et al. CURRENT CANCER DRUG TARGETS
- Serum Lactate Dehydrogenase Predicts for Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Inhibition of Mammalian Target of Rapamycin
- (2012) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials
- (2012) Hai T Tran et al. LANCET ONCOLOGY
- BAP1 loss defines a new class of renal cell carcinoma
- (2012) Samuel Peña-Llopis et al. NATURE GENETICS
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
- (2011) Viktor Gruenwald et al. BMC CANCER
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- (2011) Judith Manola et al. CLINICAL CANCER RESEARCH
- Accurate Molecular Classification of Kidney Cancer Subtypes Using MicroRNA Signature
- (2011) Youssef M. Youssef et al. EUROPEAN UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma
- (2011) Joana Heinzelmann et al. WORLD JOURNAL OF UROLOGY
- Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
- (2011) Ram N Ganapathi et al. Genome Medicine
- Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
- (2010) Toni K. Choueiri et al. BJU INTERNATIONAL
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Kidney Tumor Location Measurement Using the C Index Method
- (2010) Matthew N. Simmons et al. JOURNAL OF UROLOGY
- Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) Classification of Renal Tumours in Patients who are Candidates for Nephron-Sparing Surgery
- (2009) Vincenzo Ficarra et al. EUROPEAN UROLOGY
- MicroRNA profiling of human kidney cancer subtypes
- (2009) Petillo INTERNATIONAL JOURNAL OF ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth
- (2009) Alexander Kutikov et al. JOURNAL OF UROLOGY
- Antiangiogenesis in haematological malignancies
- (2008) William W. Li et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma
- (2008) Toni K. Choueiri et al. JOURNAL OF UROLOGY
- Targeting microRNA expression to regulate angiogenesis
- (2007) Angelika Kuehbacher et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started